Current views on chronic rejection after lung transplantation. (23rd April 2015)

• Record Type: Journal Article
• Authors: Verleden, Geert M.; Vos, Robin; Vanaudenaerde, Bart; Dupont, Lieven; Yserbyt, Jonas; Van Raemdonck, Dirk; Verleden, Stijn
• Is Part Of: Transplant international. Volume 28:Number 10(2015:Oct.)
• Page Start: 1131
• Page End: 1139
• Publication Date: 2015-04-23
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1111/tri.12579
• Languages: English
• ISSNs: 0934-0874

Abstract

<abstract abstract-type="main" id="tri12579-abs-0001"> <title>Summary</title> <p>Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term mainly to classify patients with chronic rejection after lung transplantation, although other conditions may also qualify for CLAD. Initially, only the development of a persistent and obstructive pulmonary function defect, clinically identified as bronchiolitis obliterans syndrome (BOS), was considered as chronic rejection, if no other cause could be identified. It became clear in recent years that some patients do not qualify for this definition, although they developed a chronic and persistent decrease in FEV₁, without another identifiable cause. As the pulmonary function decline in these patients was rather restrictive, this was called restrictive allograft syndrome (RAS). In the present review, we will further elaborate on these two CLAD phenotypes, with specific attention to the diagnostic criteria, the role of pathology and imaging, the risk factors, outcome, and the possible treatment options.</p> </abstract>